✨ Free AI Report
Gilead Sciences, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Gilead Sciences, Inc.
Company Research

Gilead Sciences, Inc.: Business Overview, Financials & Competitive Analysis

Gilead Sciences, Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). Strong HIV portfolio momentum with 2025 successes in Yeztugo launch and Biktarvy/Descovy growth, positioning 2026 for potential new cancer and HIV treatment launches. Gilead delivered a sharp 2025 earnings rebound, powered by HIV growth and lower IPR&D charges, while guiding to steady 2026 performance. Science named lenacapavir its 2024.

What is Gilead Sciences, Inc.'s industry? Gilead Sciences, Inc. (gilead.com) operates in Biopharmaceutical - HIV, Virology, Oncology, Immunology. AskCyborg classifies Gilead Sciences, Inc. under Biopharmaceutical - HIV, Virology, Oncology, Immunology in its company registry.

Gilead Sciences is a biopharmaceutical company that has pursued breakthroughs in medicine for more than three decades, committed to advancing innovative medicines to prevent and treat life-threatening diseases, includ...

7/ 10Strong

Cyborg Score thesis

Strong HIV portfolio momentum with 2025 successes in Yeztugo launch and Biktarvy/Descovy growth, positioning 2026 for potential...

Read the full analyst-debate transcript →
Industry Biopharmaceutical - HIV, Virology, Oncology, Immunology
4 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 7, 2026
AI-Verified Research
30+ Page Report

Get the Latest Gilead Sciences, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Gilead Sciences, Inc.

AskCyborg analysts argue the bull and bear cases for Gilead Sciences, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Gilead Sciences, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Gilead Sciences, Inc. Overview

Pro stress-test →

Gilead Sciences is a biopharmaceutical company that has pursued breakthroughs in medicine for more than three decades, committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. For 2025, Gilead achieved total revenues of $29.4 billion, with product sales excluding Veklury growing 4% to $28.0 billion.

Strategic Profile

Pro stress-test →

Gilead's HIV product sales reached $20.8 billion in 2025 (up 6%), driven by flagship treatments Biktarvy ($14.3B, +7%) and Descovy ($2.8B, +31%), establishing the company as a leading HIV care provider. The company is executing a multi-year strategy to drive growth across virology, oncology, and inflammation with planned $32 billion U.S. investment through 2030.

Competitive Landscape

Pro stress-test →

Gilead operates as a leading biopharmaceutical company in HIV treatment and prevention. Primary competitors include Merck (HIV antiretrovirals), ViiV Healthcare/GSK (Biktarvy alternatives), Johnson & Johnson (HIV/oncology), and AbbVie (virology/oncology). Gilead maintains competitive advantages through its established HIV franchise, recent approvals of innovative prevention therapies like Yeztugo, and expanding oncology pipeline.

Industry Context

Gilead Sciences, Inc. operates in Biopharmaceutical - HIV, Virology, Oncology, Immunology.

Key facts

Founded: 1987 · Headquarters: Foster City, US · Revenue: $29.4B

What the analysts stress-tested

The top findings that survived the multi-agent debate for Gilead Sciences, Inc..

  • HIV segment drove 2025 growth with Biktarvy sales up 7% to $14.3B and Descovy surging 31% to $2.8B
  • 2026 pipeline includes potential new cancer therapies and additional HIV treatment options, building on Yeztugo and Livdelzi liver disease launches
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Announced Q4 2025 revenues of $7.9B (+5% YoY) with strong HIV and liver disease product growth; declared quarterly dividend of $0.82 per share
  • February 2026Reported Phase 3 ARTISTRY-1/2 positive data for BIC/LEN investigational once-daily HIV regimen maintaining virologic suppression
  • +1 moreTrack every material event for Gilead Sciences, Inc. as it happens. Explore monitoring →
Get alerted when Gilead Sciences, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Biktarvy AlternativesHIV treatment competition→HIV TherapeuticsCompeting HIV antiretrovirals→Oncology PortfolioCancer therapy competition→Virology/HepatitisViral disease treatment→

Compare Gilead Sciences, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Gilead Sciences, Inc. operates in Biopharmaceutical - HIV, Virology, Oncology, Immunology. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical - HIV, Virology, Oncology, Immunology research →
NEW · MCP server

Ask your AI assistant about Gilead Sciences, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Gilead Sciences, Inc. and its top competitor on Cyborg Score”
“What did Gilead Sciences, Inc. do this quarter?”
“Is Gilead Sciences, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Gilead Sciences, Inc. do?+
Gilead Sciences is a biopharmaceutical company that has pursued breakthroughs in medicine for more than three decades, committed to advancing innovative medicines to prevent and treat life-threatening diseases, includ...
What is Gilead Sciences, Inc.'s Cyborg Score?+
Gilead Sciences, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Gilead Sciences, Inc.'s main competitors?+
Named competitors include Biktarvy Alternatives, HIV Therapeutics, Oncology Portfolio, Virology/Hepatitis. The full competitive landscape is in the AskCyborg report.
How can I get the full Gilead Sciences, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Gilead Sciences, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Gilead Sciences, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical - HIV research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Gilead Sciences, Inc.